Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643639 | 1.00 | PTPN11 (1.00) | PTPN11POLE3 | |
| SCHEMBL21673031 | 0.89 | PTPN11 (0.80) | PTPN11POLE3 | |
| SCHEMBL21673024 | 0.86 | PTPN11 (0.76) | PTPN11POLE3 | |
| SCHEMBL21643657 | 0.83 | PTPN11 (1.00) | PTPN11POLE3 | |
| SCHEMBL21673021 | 0.83 | PTPN11 (1.00) | PTPN11POLE3 | |
| SCHEMBL21643632 | 0.83 | PTPN11 (0.71) | PTPN11POLE3 | |
| SCHEMBL21673013 | 0.83 | PTPN11 (0.71) | PTPN11POLE3 | |
| SCHEMBL21706191 | 0.81 | PTPN11 (0.67) | PTPN11POLE3 | |
| SCHEMBL21673016 | 0.78 | PTPN11 (1.00) | PTPN11POLE3 | |
| SCHEMBL21706132 | 0.78 | PTPN11 (1.00) | PTPN11POLE3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814396-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814396-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2023-11-14 | — | — | US | disclosed |
| US-11518770-B2 | Sesquiterpenoid analogs | PURDUE RESEARCH FOUNDATION (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200040000-A1 | NOVEL SESQUITERPENOID ANALOGS | PURDUE RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814396-B2 | Sesquiterpenoid analogs | POLE3, DUSP3, STK3 | PTPN11 218/4885POLE3 1/4885 |
| US-11518770-B2 | Sesquiterpenoid analogs | POLE3, DUSP3, STK3 | PTPN11 218/4885POLE3 1/4885 |
| US-20200040000-A1 | NOVEL SESQUITERPENOID ANALOGS | POLE3, DUSP3, TP53 | PTPN11 178/4885POLE3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.